Pfizer Aktie News

Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for infectious diseases.

Ashtead has also been moving its primary listing to the New York Stock Exchange, which we believe will lift its valuation. Wells Fargo delivered strong earnings results driven by higher revenue, improved credit quality and higher investment banking fees. Merck reported earnings and revenues that beat expectations, driven by strong sales of its cancer treatment Keytruda and its pulmonary arteria...

Pfizer's stock price rocketed higher during the coronavirus pandemic.  The shares have since plunged amid a key drug failure and approaching patent cliffs.

MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 7 of this series includes Pfizer, Philip Morris International, Platinum Group Metals, Prologis and QuickLogic Corp.

These five stocks offer dividend yields of up to 9.4%. They represent different sectors, including communication services, energy, financials, healthcare, and real estate.

All three of these companies are well established, with solid growth prospects. Each faces some struggles, but all are paying shareholders to wait for stronger results.

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum. Positive developments around the pipeline support long-term financial stability, reinforcing confidence in PFE's outlook. PFE's substantial 6.7% forward dividend yield appears secure, offering attractive income in a volatile market.

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + Keytruda's expanded indications position PFE for blockbuster growth in precision oncology. The obesity pipeline, including MET-097i and a new oral candidate, could catalyze a major re-rating if Phase 3...